methyl-(1,1,2,2-tetramethyl-propyl)-amine | 29772-74-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: methyl-(1,1,2,2-tetramethyl-propyl)-amine
• 英文别名: Methyl-(1,1,2,2-tetramethyl-propyl)-amin；2,2,3-Trimethyl-3-methylamino-butan；3-Methylamino-2,2,3-trimethyl-butan；N,1,1,2,2-Pentamethylpropylamin；Methyl(2,3,3-trimethylbutan-2-yl)amine；N,2,3,3-tetramethylbutan-2-amine
• CAS: 29772-74-5
• 化学式: C₈H₁₉N
• mdl: MFCD19217801
• 分子量: 129.246
• InChiKey: SBNNYCBGSSSIAM-UHFFFAOYSA-N

物化性质

• 沸点：
  141-142 °C
• 密度：
  0.762±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  五甲基乙醇 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 乙醚 、 溶剂黄146 为溶剂， 生成 methyl-(1,1,2,2-tetramethyl-propyl)-amine
  参考文献：
  名称：

  Vejdelek,Z.J. et al., Collection of Czechoslovak Chemical Communications, 1970, vol. 35, p. 2814 - 2830

  摘要：

  DOI：

文献信息

• Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
  申请人：Saksena K. Anil

  公开号：US20070032433A1

  公开（公告）日：2007-02-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明揭示了具有HCV蛋白酶抑制活性的新化合物，以及制备这些化合物的方法。在另一种实施方式中，本发明揭示了包含这些化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• [EN] MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE<br/>[FR] INHIBITEURS MACROCYCLIQUES DE LA SERINE PROTEASE NS3 DU VIRUS DE L'HEPATITE C
  申请人：SCHERING CORP

  公开号：WO2005030796A1

  公开（公告）日：2005-04-07

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as pharmaceutical compositions comprising such compounds and methods of using them to treat disorders associated with the HCV protease. The novel compounds typically include a 15-20 member macrocycle and have the general structure of structural Formula (1): wherein Z', L', M', R1, X and D are defined herein.

  本发明揭示了一种新型化合物，其具有HCV蛋白酶抑制活性，以及包含这些化合物的制药组合物和使用它们治疗与HCV蛋白酶相关的疾病的方法。这些新型化合物通常包括一个15-20成员的大环，并具有以下结构式（1）的一般结构，其中Z'、L'、M'、R1、X和D在此被定义。
• Substituted amides
  申请人：Lin Linus S.

  公开号：US20080194645A1

  公开（公告）日：2008-08-14

  Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

  结构式（I）的新化合物是大麻素-1（CB1）受体的拮抗剂和/或反向激动剂，并且可用于治疗、预防和抑制由CB1受体介导的疾病。本发明的化合物可用作中枢神经系统药物，用于治疗精神病、记忆障碍、认知障碍、偏头痛、神经病、神经炎性疾病，包括多发性硬化症和格林-巴利综合症以及病毒性脑炎、脑血管意外和头部创伤的炎症后遗症、焦虑症、压力、癫痫、帕金森病、运动障碍和精神分裂症。这些化合物还可用于治疗物质滥用障碍、肥胖症或进食障碍以及哮喘、便秘、慢性肠假性梗阻和肝硬化。
• AZO-SUBSTITUTED PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATING VIRAL INFECTIONS
  申请人：Kwong Cecil D.

  公开号：US20110286964A1

  公开（公告）日：2011-11-24

  The present invention provides compounds of Formula (I): (Chemical formula should be inserted here as it appears on abstract in paper form) (I) and tautomers, isomers, and esters of said compounds, and pharmaceutically acceptable salts, solvates, and prodrugs of said compounds, wherein each of R, R 1 , X, Y, Z, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 18 , R 19 , and n is selected independently and as defined herein. Compositions comprising such compounds are also provided. The compounds of the invention are effective as inhibitors of HCV, and are useful, alone and together with other therapeutic agents, in treating or preventing dieases or disorders such as viral infections and virus-related disorders.

  本发明提供了式(I)的化合物：（将在论文中以纸质形式出现的化学式插入此处）（I）及其互变异构体、异构体和酯类，以及所述化合物的药学上可接受的盐、溶剂化物和前药，其中每个R、R1、X、Y、Z、R2、R3、R4、R5、R6、R7、R8、R9、R18、R19和n均是独立选择并如所定义。还提供了包含此类化合物的组合物。本发明的化合物是HCV抑制剂，可用于治疗或预防病毒感染和与病毒相关的疾病或障碍，单独或与其他治疗剂一起使用。
• HETEROCYCLIC COMPOUND
  申请人：BANNO Yoshihiro

  公开号：US20120270865A2

  公开（公告）日：2012-10-25

  Provision of a prophylactic or therapeutic agent for diabetes, which has superior efficacy. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

  提供一种预防或治疗糖尿病的药物，其疗效优越。一种由该式表示的化合物：其中每个符号如规范中所述，或其盐。